AC Immune

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AC Immune and other ETFs, options, and stocks.

About ACIU

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. 

CEO
Martin Zügel
CEOMartin Zügel
Employees
122
Employees122
Headquarters
Lausanne, Vaud
HeadquartersLausanne, Vaud
Founded
2003
Founded2003
Employees
122
Employees122

ACIU Key Statistics

Market cap
282.93M
Market cap282.93M
Price-Earnings ratio
-5.14
Price-Earnings ratio-5.14
Dividend yield
Dividend yield
Average volume
197.77K
Average volume197.77K
High today
$2.85
High today$2.85
Low today
$2.78
Low today$2.78
Open price
$2.82
Open price$2.82
Volume
100.49K
Volume100.49K
52 Week high
$4.00
52 Week high$4.00
52 Week low
$2.10
52 Week low$2.10

Stock Snapshot

As of today, AC Immune(ACIU) shares are valued at $2.78. The company's market cap stands at 282.93M, with a P/E ratio of -5.14.

As of 2026-09-08, AC Immune(ACIU) stock has fluctuated between $2.78 and $2.85. The current price stands at $2.78, placing the stock +0.2% above today's low and -2.5% off the high.

AC Immune(ACIU) shares are trading with a volume of 100.49K, against a daily average of 197.77K.

In the last year, AC Immune(ACIU) shares hit a 52-week high of $4.00 and a 52-week low of $2.10.

In the last year, AC Immune(ACIU) shares hit a 52-week high of $4.00 and a 52-week low of $2.10.

ACIU News

TipRanks 5d
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board

The latest update is out from AC Immune SA ( (ACIU) ). On September 2, 2026, AC Immune SA called an Extraordinary General Meeting set for October 2, 2026, as p...

TipRanks 6d
AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus

AC Immune (ACIU) announced an update on their ongoing clinical study. AC Immune SA is running a Phase 1 trial called a single-center, double-blind, randomized,...

People also own

Based on the portfolios of people who own ACIU. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.